Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington, involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer.

It operated a laboratory and production facility in Hamilton, Montana.

In 2005, the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa.

[1] GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub.